✨ Free AI Report
Spyre Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Spyre Therapeutics, Inc.
Company Research

Spyre Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Spyre Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage antibody biotech with near-term catalysts (6 POC readouts in 2026) in large IBD and rheumatic disease markets, backed by strong cash position and experienced commercial leadership. SKYLINE platform trial in ulcerative colitis is recruiting faster than expected with SPY001 enrollment complete ahead of schedule. The company has strong.

What is Spyre Therapeutics, Inc.'s industry? Spyre Therapeutics, Inc. (spyre.com) operates in Biotechnology - Immunology & Inflammation Therapeutics. AskCyborg classifies Spyre Therapeutics, Inc. under Biotechnology - Immunology & Inflammation Therapeutics in its company registry.

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Th...

7/ 10Strong

Cyborg Score thesis

Clinical-stage antibody biotech with near-term catalysts (6 POC readouts in 2026) in large IBD and rheumatic disease markets,...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunology & Inflammation Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Spyre Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Spyre Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Spyre Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Spyre Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Spyre Therapeutics, Inc. Overview

Pro stress-test →

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. The company is positioned for a transformational 2026 with six proof-of-concept readouts expected across its SKYLINE and SKYWAY Phase 2 trials, targeting patient populations with limited treatment options.

Strategic Profile

Pro stress-test →

The company combines best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to create next-generation IBD and immune-mediated disease products. Spyre recently expanded its leadership by appointing Kate Tansey Chevlen as Chief Commercial Officer, a seasoned biopharma executive with nearly two decades of experience at Amgen.

Competitive Landscape

Pro stress-test →

Spyre operates in the highly competitive IBD and rheumatic disease therapeutics market dominated by established players like Johnson & Johnson, AbbVie, and Eli Lilly. The company differentiates through extended half-life antibodies and rational combination approaches, competing against other emerging biotech companies like Morphic Holding, Arena Pharmaceuticals, and others. Phathom Pharmaceuticals is noted as one of approximately 72 competitors in the space.

Industry Context

Spyre Therapeutics, Inc. operates in Biotechnology - Immunology & Inflammation Therapeutics.

Key facts

Founded: 2013 · Headquarters: Waltham, Massachusetts · Market cap: $2.45B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Spyre Therapeutics, Inc..

  • Six expected proof-of-concept readouts in 2026 provide multiple near-term value inflection points across IBD and rheumatic disease indications
  • Extended half-life antibody platform offers potential therapeutic advantages in convenience and efficacy versus standard-of-care monotherapies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Spyre reports Q4 2025 results and confirms 6 POC readouts on track for 2026 with $757M cash position
  • February 2026Wells Fargo raises price target to $50; Leerink Partners upgrades to strong-buy; mixed sentiment from Weiss Ratings (sell)
  • +1 moreTrack every material event for Spyre Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Spyre Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Skyrizi / RinvoqIL-23 and JAK inhibitors for IBD and rheumatic diseases→Stelara / TaltzIL-12/23 and IL-17A biologics for IBD and psoriasis→OlumiantJAK inhibitor for rheumatoid arthritis→

Compare Spyre Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Spyre Therapeutics, Inc. operates in Biotechnology - Immunology & Inflammation Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunology & Inflammation Therapeutics research →
NEW · MCP server

Ask your AI assistant about Spyre Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Spyre Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Spyre Therapeutics, Inc. do this quarter?”
“Is Spyre Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Spyre Therapeutics, Inc. do?+
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Th...
What is Spyre Therapeutics, Inc.'s Cyborg Score?+
Spyre Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Spyre Therapeutics, Inc.'s main competitors?+
Named competitors include Skyrizi / Rinvoq, Stelara / Taltz, Olumiant. The full competitive landscape is in the AskCyborg report.
How can I get the full Spyre Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Spyre Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Spyre Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.